Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-ALLYL-5-AMIDINOAMINOOXY-PROPYLOXY-3-CHLORO-N-CYCLOPENTYLBENZAMIDE
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
N-Allyl-5-amidinoaminooxy-propyloxy-3-chloro-N-cyclopentylbenzamide is an experimental small molecule compound belonging to the class of organic compounds known as 3-halobenzoic acids and derivatives. It has a molecular formula of C19H27ClN4O3 and a molecular weight of approximately 394.9 Da[1][2][6]. The compound is also referred to by its DrugBank ID (DB06859), PDB ligand code (14A), and CHEMBL ID (CHEMBL123440). There are no approved indications, clinical trials, or patents associated with this molecule, and it is not approved for use in any country[1]. Its mechanism of action, biological targets, developer(s), manufacturer(s), route(s) of administration, and therapeutic area remain uncharacterized in public databases as of June 2025.
- Other names
- 3-[3-(carbamimidamidooxy)propoxy]-5-chloro-N-cyclopentyl-N-prop-2-enylbenzamide3-(3-carbamimidamidooxypropoxy)-5-chloro-N-cyclopentyl-N-prop-2-enyl-benzamide
Beyond the preview
Go deeper on N-ALLYL-5-AMIDINOAMINOOXY-PROPYLOXY-3-CHLORO-N-CYCLOPENTYLBENZAMIDE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on N-ALLYL-5-AMIDINOAMINOOXY-PROPYLOXY-3-CHLORO-N-CYCLOPENTYLBENZAMIDE.